Diabetes monitoring - albuminuria: Frequently asked questions

Australian Family Physician

Volumn 36, Issue 9, 2007, Pages 713-715

  Phillips, Patrick J ^a   Phillipov, George ^a  

^a QUEEN ELIZABETH HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMINOID; CREATININE;

ALBUMINURIA; DIABETIC ANGIOPATHY; DIABETIC NEPHROPATHY; DISEASE MANAGEMENT; GENERAL PRACTICE; GLOMERULUS FILTRATION RATE; GLUCOSE BLOOD LEVEL; HUMAN; METHODOLOGY; MONITORING; REVIEW;

ALBUMINS; ALBUMINURIA; BLOOD GLUCOSE; CREATININE; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DISEASE MANAGEMENT; FAMILY PRACTICE; GLOMERULAR FILTRATION RATE; HUMANS; MONITORING, PHYSIOLOGIC;

EID: 36048970326     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. STENO-2 Study. N Engl J Med 2003;348:389-93.
2. Harris P, Mann L, Phillips P, Webster C. Diabetes management in general practice. 12th edn. Canberra: Diabetes Australia and the RACGP, 2007.
3. Phillipov G, Phillips PJ. Variability of urinary albumin excretion in patients with microalbuminuria. Diabetes Care 1994;17:425-7.
4. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870-8.
5. Lewis E, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
6. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetalogia 1999;42:263-85.
7. Mogensen CE. Progression of nephropathy in long term diabetics with proteinuria and effect of initial antihypertensive treatment. Scand J Clin Lab Invest 1976;36:383-8.